Did you get the reference?

🎯 Dr. Tomas Pulido presented Out of the woods: High-altitude PAH. This subset of PAH is seen frequently in certain areas of south America and tend to improve with meds and moving to low altitude areas.

🎯 Dr Valentina Stosor presented Shake it Off: HIV associated PAH. HIV infection induces changes in the PA other than from direct infection. Drugs interactions are frequent between PA vasodilators and ART.

🎯 Dr Camila Loureiro presented I forgot that you existed: Schistosomiasis-Associated pulmonary arterial hypertension. Schistosoma is extremely frequent in certain areas of Africa, Asia and Brazil. We dipped dig on the treatments and diagnosis of such a rare subset of disease.

🎯 Dr Hooman Poor presented Bad Blood: Pulmonary Hypertension, Hematologic disorder and Bone Marrow Transplant. Sickle cell, dasatinib associated PAH and mieloproliferative disease

🎯 Dr Arun Jose presented: When the liver is the source of evil: porto-pulmonary HTN and liver transplantation.
PoP-PH is different from Hepato-pulmonary syndrome, which tends to regress after liver transplant. Liver transplant can improve PoP-PH though PH can persist.

🎯 Dr Arun Jose presented: When the liver is the source of evil: porto-pulmonary HTN and liver transplantation.
PoP-PH is different from Hepato-pulmonary syndrome, which tends to regress after liver transplant. Liver transplant can improve PoP-PH though PH can persist.

We finished with Dr David Jenkins and CTEPH talks.

When confirmed CTEPH we should ask:

🟢is patient operable? If YES PTE
NO?

🟢Can we do BPA?
NO?

🟢Riociguat

New direction? Can we combine such treatments for high risk patients?

We also talked about group 3 PH with Dr Shlobin Oksana. The different pathophysiology of it and possible treatment options.

Differentiate between:

🟢COPD-PH
🟢CPFE-PH
🟢ILD-PH

More studies are needed with better characterisation of PFTs for therapeutic target.